ClinicalTrials.gg
CompletedNCT00174317Updated Dec 5, 2006

Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

A Phase 4 interventional study of Celecoxib and Diclofenac in Osteoarthritis, Hip, sponsored by Pfizer. Completed at 44 sites in United Kingdom. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2006-12-05.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Osteoarthritis, Hip with a site in United Kingdom — 5 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Hip · United Kingdom.

Enrollment
8th of 23
250 · median 125
Started
2003
the only one that year
Phase 4
2 of 32
none open now
Registered
3rd of 32
by date
Lead sponsor
2 of 32
Pfizer

Among the 32 studies in Osteoarthritis, Hip with a site in United Kingdom, this one is the 8th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2003, is one of 2 in phase 4, and was the 3rd registered.

Osteoarthritis, Hip

641 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

5 of the 32 studies in Osteoarthritis, Hip with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Osteoarthritis, Hip with a site in United Kingdom, or all of them as a file.
02

Study summary

To determine if celecoxib 200 mg once daily is as effective as diclofenac 50 mg three times daily in the treatment of pain symptoms associated with osteoarthritis of the hip

03

Conditions studied

  • Osteoarthritis, Hip

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with osteoarthritis of hip and requiring joint replacement
  • Eligible for chronic therapy with an NSAID

Exclusion criteria

Exclusion Criteria:

  • Hip surgery anticipated within 8 calendar weeks after first visit
  • Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration (within 60 days of first visit)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
250 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in patient assessment of arthritis pain on walking VAS (Visual Analog Scale) as measured on a 0-100 mm scale at week 6 compared to baseline

Secondary outcomes

  1. Change in patient assessment of arthritis pain on walking VAS (Visual Analog Scale) as measured on a 0-100 mm scale at week 12 compared to baseline.

  2. Change in patients global assessment of arthritis between treatment groups.

07

Study locations

44 sites
  • Pfizer Investigational Site
    Aston Clinton, Bucks GP22 5LB, United Kingdom
  • Pfizer Investigational Site
    Ely, Cambs CB7 5JD, United Kingdom
  • Pfizer Investigational Site
    St. Austell, Cornwall PL26 7DL, United Kingdom
  • Pfizer Investigational Site
    Lancaster, England LA1 2LG, United Kingdom
  • Pfizer Investigational Site
    Sheffield, England S3 9DA, United Kingdom
  • Pfizer Investigational Site
    Newport, Gwent NP20 4SZ, United Kingdom
  • Pfizer Investigational Site
    Chingford, London E4 6UN, United Kingdom
  • Pfizer Investigational Site
    Harrow, Middlesex HA3 7LT, United Kingdom
  • Pfizer Investigational Site
    Greenisland, Carrickfergus, Northern Ireland BT38 8TP, United Kingdom
  • Pfizer Investigational Site
    Oxford, Oxon OX3 7LD, United Kingdom
  • Pfizer Investigational Site
    Greenock, Renfrewshire PA16 0XN, United Kingdom
  • Pfizer Investigational Site
    Barry, South Glamorgan CF62 7EB, United Kingdom
  • Pfizer Investigational Site
    Barnsley, South Yorkshire S75 2EP, United Kingdom
  • Pfizer Investigational Site
    Ashford, Surrey TW15 3AA, United Kingdom
  • Pfizer Investigational Site
    Newcastle-Upon-Tyne, Tyne & Wear NE7 7DN, United Kingdom
  • Pfizer Investigational Site
    Trowbridge, Wiltshire BA14 9AR, United Kingdom
  • Pfizer Investigational Site
    Aberdeen, AB15 6XS, United Kingdom
  • Pfizer Investigational Site
    Amersham, HP7 0JD, United Kingdom
  • Pfizer Investigational Site
    Bath, BA1 2SR, United Kingdom
  • Pfizer Investigational Site
    Bath, BA2 4BZ, United Kingdom
  • Pfizer Investigational Site
    Belfast, United Kingdom
  • Pfizer Investigational Site
    Bradford, BD9 6RJ, United Kingdom
  • Pfizer Investigational Site
    Cardiff, CF23 5SY, United Kingdom
  • Pfizer Investigational Site
    Carshalton, SM5 1AA, United Kingdom
  • Pfizer Investigational Site
    Chertsey, KT16 0PZ, United Kingdom
  • Pfizer Investigational Site
    Edinburgh, EH4 2XU, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G12 0YN, United Kingdom
  • Pfizer Investigational Site
    Lancaster, LA1 4RP, United Kingdom
  • Pfizer Investigational Site
    Leystonstone, London, E11 1NR, United Kingdom
  • Pfizer Investigational Site
    Liverpool, CH49 5PE, United Kingdom
  • Pfizer Investigational Site
    Liverpool, L9 7AL, United Kingdom
  • Pfizer Investigational Site
    London, SE5 9RS, United Kingdom
  • Pfizer Investigational Site
    Manchester, M8 5RB, United Kingdom
  • Pfizer Investigational Site
    Northampton, NN1 5BD, United Kingdom
  • Pfizer Investigational Site
    Norwich, NR7 4UY, United Kingdom
  • Pfizer Investigational Site
    Nuneaton, CV10 7DJ, United Kingdom
  • Pfizer Investigational Site
    Peterborough, PE7 3JL, United Kingdom
  • Pfizer Investigational Site
    Sheffield, S5 7AU, United Kingdom
  • Pfizer Investigational Site
    Southampton, SO16 6YD, United Kingdom
  • Pfizer Investigational Site
    Truro, TR1 3LJ, United Kingdom
  • Pfizer Investigational Site
    Wansford, PE8 6PL, United Kingdom
  • Pfizer Investigational Site
    Watford, WD1 8HB, United Kingdom
  • Pfizer Investigational Site
    Westbury, BA13 3JD, United Kingdom
  • Pfizer Investigational Site
    Wigan, WN6 9EP, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Aug 2003
Completion
Feb 2005
Last update
Dec 5, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Dec 5, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00174317
Lead sponsor
Pfizer
First posted
Sep 15, 2005
Start date
Aug 2003
Completion
Feb 2005
Last update
Dec 5, 2006

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Diclofenac

Start the discussion